Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Chentoufi, Aziz Alami ^a,b   Benmohamed, Lbachir ^c  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERPES VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORNEA DISEASE; DENDRITIC CELL; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER OPHTHALMICUS; HERPETIC STROMAL KERATITIS; HUMAN; INNATE IMMUNITY; MACROPHAGE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VIRUS REACTIVATION; ANIMAL; EYE DISEASE; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; IMMUNOLOGY; PATHOLOGY; VIROLOGY;

ANIMALS; EYE DISEASES; HERPES GENITALIS; HERPES SIMPLEX; HUMANS; IMMUNITY, MUCOSAL; KERATITIS, HERPETIC;

MLCS; MLOWN;

EID: 84872800289     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/149135     Document Type: Review

References (247)

1. Bettahi I., Zhang X., Afifi R. E., BenMohamed L., Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunology 2006 19 2 220 236 2-s2.0-33745930525 10.1089/vim.2006.19.220 (Pubitemid 44050321)
2. + T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunology 2009 2 2 129 143 2-s2.0-60549095850 10.1038/mi.2008.81
3. + T cell immunity against herpes: importance of MyD88. Journal of Immunology 2012 189 9 4496 4509 10.4049/jimmunol.1201121
4. Gilbert M., Li X., Petric M., Krajden M., Isaac-Renton J. L., Ogilvie G., Rekart M. L., Using centralized laboratory data to monitor trends in Herpes Simplex Virus type 1 and 2 infection in British Columbia and the changing etiology of genital Herpes. Canadian Journal of Public Health 2011 102 3 225 229 2-s2.0-79960791328
5. Belshe R. B., Leone P. A., Bernstein D. I., Wald A., Levin M. J., Stapleton J. T., Gorfinkel I., Ashley Morrow R. L., Ewell M. G., Stokes-Riner A., Dubin G., Heineman T. C., Schulte J. M., Deal C. D., Efficacy results of a trial of a herpes simplex vaccine. The New England Journal of Medicine 2012 366 1 34 43 10.1056/NEJMoa1103151
6. Allen S. J., Mott K. R., Chentoufi A. A., BenMohamed L., Wechsler S. L., Ballantyne C. M., Ghiasi H., CD11c controls herpes simplex virus 1 responses to limit virus replication during primary infection. Journal of Virology 2011 85 19 9945 9955 10.1128/JVI.05208-11
7. Chentoufi A. A., Kritzer E., Yu D. M., Nesburn A. B., Benmohamed L., Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clinical and Developmental Immunology 2012 2012 16 187585 10.1155/2012/187585
8. +-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 2011 29 35 5824 5836 2-s2.0-79960708453 10.1016/j.vaccine.2011.06.083
9. Kimberlin D. W., Whitley R. J., Wan W., Powell D. A., Storch G., Ahmed A., Palmer A., Sánchez P. J., Jacobs R. F., Bradley J. S., Robinson J. L., Shelton M., Dennehy P. H., Leach C., Rathore M., Abughali N., Wright P., Frenkel L. M., Brady R. C., van Dyke R., Weiner L. B., Guzman-Cottrill J., McCarthy C. A., Griffin J., Jester P., Parker M., Lakeman F. D., Kuo H., Lee C. H., Cloud G. A., Oral acyclovir suppression and neurodevelopment after neonatal herpes. The New England Journal of Medicine 2011 365 14 1284 1292 10.1056/NEJMoa1003509
10. Wolfert S. I. M., de Jong E. P., Vossen A. C. T. M., Zwaveling J., Te Pas A. B., Walther F. J., Lopriore E., Diagnostic and therapeutic management for suspected neonatal herpes simplex virus infection. Journal of Clinical Virology 2011 51 1 8 11 2-s2.0-79953731935 10.1016/j.jcv.2011.02.008
11. Gershon A. A., Neonatal herpes simplex infection and the Three Musketeers. The New England Journal of Medicine 2011 365 14 1338 1339 10.1056/NEJMe1107953
12. Koelle D. M., Corey L., Herpes simplex: insights on pathogenesis and possible vaccines. Annual Review of Medicine 2008 59 381 395 2-s2.0-39649109256 10.1146/annurev.med.59.061606.095540 (Pubitemid 351287944)
13. Wilhelmus K. R., Beck R. W., Moke P. S., Dawson C. R., Barron B. A., Jones D. B., Kaufman H. E., Kurinij N., Stulting R. D., Sugar J., Cohen E. J., Hyndiuk R. A., Ashell P. A., Acyclovir for the prevention of recurrent herpes simplex virus eye disease. The New England Journal of Medicine 1998 339 5 300 306 10.1056/NEJM199807303390503 (Pubitemid 28366418)
14. Leflore S., Anderson P. L., Fletcher C. V., A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Safety 2000 23 2 131 142 2-s2.0-0033854454 (Pubitemid 30601401)
15. Danve-Szatanek C., Aymard M., Thouvenot D., Morfin F., Agius G., Bertin I., Billaudel S., Chanzy B., Coste-Burel M., Finkielsztejn L., Fleury H., Hadou T., Henquell C., Lafeuille H., Lafon M. E., Le Faou A., Legrand M. C., Maille L., Mengelle C., Morand P., Morinet F., Nicand E., Omar S., Picard B., Pozzetto B., Puel J., Raoult D., Scieux C., Segondy M., Seigneurin J. M., Teyssou R., Zandotti C., Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. Journal of Clinical Microbiology 2004 42 1 242 249 2-s2.0-9144232252 10.1128/JCM.42.1.242-249.2004 (Pubitemid 38082727)
16. Leung D. T., Sacks S. L., Current treatment options to prevent perinatal transmission of herpes simplex virus. Expert Opinion on Pharmacotherapy 2003 4 10 1809 1819 2-s2.0-0142241282 10.1517/14656566.4.10.1809 (Pubitemid 37322365)
17. Oram R. J., Marcellino D., Strauss D., Gustafson E., Talarico C. L., Root A. K., Sharma P. L., Thompson K., Fingeroth J. D., Crumpacker C., Herold B. C., Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. Journal of Infectious Diseases 2000 181 4 1458 1461 2-s2.0-0034122431 10.1086/315387 (Pubitemid 30252555)
18. Stránská R., Schuurman R., Nienhuis E., Goedegebuure I. W., Polman M., Weel J. F., Wertheim-Van Dillen P. M., Berkhout R. J. M., van Loon A. M., Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. Journal of Clinical Virology 2005 32 1 7 18 2-s2.0-9644252743 10.1016/j.jcv.2004.04.002 (Pubitemid 39575009)
19. Czartoski T., Liu C., Koelle D. M., Schmechel S., Kalus A., Wald A., Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. Journal of Clinical Microbiology 2006 44 4 1584 1586 2-s2.0-33645945267 10.1128/JCM.44.4.1584-1586.2006
20. Schinazi R. F., del Bene V., Scott R. T., Dudley-Thorpe J. B., Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. Journal of Antimicrobial Chemotherapy 1986 18 supplement B 127 134 2-s2.0-0022976429 (Pubitemid 17199059)
21. Bernstein D. I., Stanberry L. R., Herpes simplex virus vaccines. Vaccine 1999 17 13-14 1681 1689 2-s2.0-0344267652 10.1016/S0264-410X(98)00434-4 (Pubitemid 29138901)
22. Stanberry L. R., Herpes simplex virus vaccines as immunotherapeutic agents. Trends in Microbiology 1995 3 6 244 247 2-s2.0-0029015680 10.1016/S0966-842X(00)88933-7
23. Nesburn A. B., Bettahi I., Zhang X., Zhu X., Chamberlain W., Afifi R. E., Wechsler S. L., Benmohamed L., Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocular Surface 2006 4 4 178 187 2-s2.0-34447293406 (Pubitemid 351907722)
24. Sperling R. S., Fife K. H., Warren T. J., Dix L. P., Brennan C. A., The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sexually Transmitted Diseases 2008 35 3 286 290 2-s2.0-42949175556 10.1097/OLQ.0b013e31815b0132 (Pubitemid 351619534)
25. Fife K. H., Warren T. J., Justus S. E., Heitman C. K., An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sexually Transmitted Diseases 2008 35 7 666 673 2-s2.0-50649110554 10.1097/OLQ.0b013e31816d1f42
26. Cates W. Jr., Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sexually Transmitted Diseases 1999 26 4 S2 S7 2-s2.0-0345722746 (Pubitemid 29177834)
27. Abu-Raddad L. J., Magaret A. S., Celum C., Wald A., Longini I. M. Jr., Self S. G., Corey L., Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 2008 3 5 2-s2.0-48449099125 10.1371/journal.pone.0002230 e2230
28. Des Jarlais D. C., Hagan H., Arasteh K., McKnight C., Perlman D., Friedman S. R., Herpes simplex virus-2 and HIV among noninjecting drug users in New York City. Sexually Transmitted Diseases 2007 34 11 923 927 2-s2.0-37349020961 10.1097/OLQ.0b013e3180ca9647 (Pubitemid 350287509)
29. Friedman S. R., Bolyard M., Sandoval M., Mateu-Gelabert P., Maslow C., Zenilman J., Relative prevalence of different sexually transmitted infections in HIV-discordant sexual partnerships: data from a risk network study in a high-risk New York neighbourhood. Sexually Transmitted Infections 2008 84 1 17 18 2-s2.0-38849149668 10.1136/sti.2007.026815 (Pubitemid 351195844)
30. Lubinski J., Nagashunmugam T., Friedman H. M., Viral interference with antibody and complement. Seminars in Cell and Developmental Biology 1998 9 3 329 337 2-s2.0-0032087482 (Pubitemid 128350231)
31. Herget G. W., Riede U. N., Schmitt-Gräff A., Lübbert M., Neumann-Haefelin D., Köhler G., Generalized herpes simplex virus infection in an immunocompromised patient-report of a case and review of the literature. Pathology Research and Practice 2005 201 2 123 129 2-s2.0-15944411391 10.1016/j.prp.2004.12.003 (Pubitemid 40443826)
32. Wald A., Link K., Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. Journal of Infectious Diseases 2002 185 1 45 52 2-s2.0-0036137322 10.1086/338231 (Pubitemid 34043015)
33. Milligan G. N., Bernstein D. I., Bourne N., T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. Journal of Immunology 1998 160 12 6093 6100 2-s2.0-0032526336 (Pubitemid 28298073)
34. Kuklin N. A., Daheshia M., Chun S., Rouse B. T., Role of mucosal immunity in herpes simplex virus infection. Journal of Immunology 1998 160 12 5998 6003 2-s2.0-0032526588 (Pubitemid 28298061)
35. Langenberg A. G. M., Corey L., Ashley R. L., Leong W. P., Straus S. E., A prospective study of new infections with herpes simplex virus type 1 and type 2. The New England Journal of Medicine 1999 341 19 1432 1438 2-s2.0-0033523873 10.1056/NEJM199911043411904 (Pubitemid 29513459)
36. Wald A., Zeh J., Selke S., Warren T., Ryncarz A. J., Ashley R., Krieger J. N., Corey L., Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. The New England Journal of Medicine 2000 342 12 844 850 2-s2.0-0034704798 10.1056/NEJM200003233421203 (Pubitemid 30165207)
37. Koelle D. M., Corey L., Recent progress in herpes simplex virus immunobiology and vaccine research. Clinical Microbiology Reviews 2003 16 1 96 113 2-s2.0-0037237569 10.1128/CMR.16.1.96-113.2003 (Pubitemid 36114709)
38. O'Farrell N., Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. Sexually Transmitted Infections 1999 75 6 377 384 2-s2.0-0033379261 (Pubitemid 30056231)
39. Weiss H., Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004 11 supplement 1 24A 35A 2-s2.0-1942531336 (Pubitemid 38529332)
40. Malkin J. E., Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004 11 supplement 1 2A 23A 2-s2.0-1942435283
41. Bacon T. H., Levin M. J., Leary J. J., Sarisky R. T., Sutton D., Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews 2003 16 1 114 128 2-s2.0-0037244124 10.1128/CMR.16.1.114-128.2003 (Pubitemid 36114710)
42. Sarisky R. T., Bacon T. H., Boon R. J., Duffy K. E., Esser K. M., Leary J., Locke L. A., Nguyen T. T., Quail M. R., Saltzman R., Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Archives of Virology 2003 148 9 1757 1769 2-s2.0-0141786611 10.1007/s00705-003-0124-7 (Pubitemid 37144179)
43. Shin Y. K., Weinberg A., Spruance S., Bernard M., Bacon T. H., Boon R. J., Levin M. J., Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis. Journal of Infectious Diseases 2003 187 8 1241 1245 2-s2.0-0037447109 10.1086/373993
44. Ziyaeyan M., Alborzi A., Japoni A., Kadivar M., Davarpanah M. A., Pourabbas B., Abassian A., Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. International Journal of Dermatology 2007 46 12 1263 1266 2-s2.0-37549046794 10.1111/j.1365-4632.2007.03449.x
45. Ziyaeyan M., Japoni A., Roostaee M. H., Salehi S., Soleimanjahi H., A serological survey of herpes simplex virus type 1 and 2 immunity in pregnant women at labor stage in Tehran, Iran. Pakistan Journal of Biological Sciences 2007 10 1 148 151 2-s2.0-33846416514 (Pubitemid 46142375)
46. Pereira C. F., Rutten K., Stránská R., Huigen M. C. D. G., Aerts P. C., de Groot R. J., Egberink H. F., Schuurman R., Nottet H. S. L. M., Spectrum of antiviral activity of o-(acetoxyphenyl)hept-2-ynyl sulphide (APHS). International Journal of Antimicrobial Agents 2005 25 5 419 426 2-s2.0-17644401316 10.1016/j.ijantimicag.2004.11.011 (Pubitemid 40558775)
47. Shin Y. K., Cai G. Y., Weinberg A., Leary J. J., Levin M. J., Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. Journal of Clinical Microbiology 2001 39 3 913 917 2-s2.0-0035098316 10.1128/JCM.39.3.913-917.2001 (Pubitemid 32209699)
48. Fleming D. T., Mcquillan G. M., Johnson R. E., Nahmias A. J., Aral S. O., Lee F. K., Louis M. E. S., Herpes simplex virus type 2 in the United States, 1976 to 1994. The New England Journal of Medicine 1997 337 16 1105 1111 2-s2.0-0030744945 10.1056/NEJM199710163371601 (Pubitemid 27444100)
49. Stanberry L. R., Cunningham A. L., Mindel A., Scott L. L., Spruance S. L., Aoki F. Y., Lacey C. J., Prospects for control of herpes simplex virus disease through immunization. Clinical Infectious Diseases 2000 30 3 549 566 2-s2.0-0034034204 10.1086/313687 (Pubitemid 30205304)
50. Stanberry L. R., Spruance S. L., Cunningham A. L., Bernstein D. I., Mindel A., Sacks S., Tyring S., Aoki F. Y., Slaoui M., Denis M., Vandepapeliere P., Dubin G., Glycoprotein-D-adjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 2002 347 21 1652 1661 2-s2.0-0037153024 10.1056/NEJMoa011915 (Pubitemid 35340783)
51. Handel S., Klingler E. J., Washburn K., Blank S., Schillinger J. A., Population-based surveillance for neonatal herpes in New York City, April 2006-September 2010. Sexually Transmitted Diseases 2011 38 8 705 711 2-s2.0-79961030812 10.1097/OLQ.0b013e31821b178f
52. Shann F., Chiletti R., Neonatal herpes virus infection: duration of extracorporeal support and the dose of acyclovir. Pediatric Critical Care Medicine 2011 12 5 605 606
53. Thompson C., Whitley R., Neonatal herpes simplex virus infections: where are we now? Advances in Experimental Medicine and Biology 2011 697 221 230 2-s2.0-79952277641
54. Brown Z. A., Benedetti J., Ashley R., Burchett S., Selke S., Berry S., Vontver L. A., Corey L., Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. The New England Journal of Medicine 1991 324 18 1247 1252 2-s2.0-0025845506
55. Gardella C., Brown Z., Wald A., Selke S., Zeh J., Morrow R. A., Corey L., Risk factors for herpes simplex virus transmission to pregnant women: a couples study. American Journal of Obstetrics and Gynecology 2005 193 6 1891 1899 2-s2.0-28444435970 10.1016/j.ajog.2005.07.041 (Pubitemid 41737611)
56. Beauman J. G., Genital herpes: a review. American Family Physician 2005 72 8 1527 1534 2-s2.0-30744459614
57. Cleary K. L., Paré E., Stamilio D., Macones G. A., Type-specific screening for asymptomatic herpes infection in pregnancy: a decision analysis. BJOG: An International Journal of Obstetrics and Gynaecology 2005 112 6 731 736 2-s2.0-20744432479 10.1111/j.1471-0528.2005.00540.x (Pubitemid 40852840)
58. Tanchev S., Shentov B., Herpes simplex virus infection in pregnancy and transmission to neonatal. Akusherstvo i Ginekologiia 2005 44 6 31 35 2-s2.0-58149232599
59. Donoval B. A., Passaro D. J., Klausner J. D., The public health imperative for a neonatal herpes simplex virus infection surveillance system. Sexually Transmitted Diseases 2006 33 3 170 174 2-s2.0-33645961309 10.1097/01.olq.0000187203.27918.45 (Pubitemid 43790826)
60. Brown Z. A., Gardella C., Wald A., Morrow R. A., Corey L., Genital herpes complicating pregnancy. Obstetrics and Gynecology 2005 106 4 845 856 2-s2.0-25444515225 (Pubitemid 41362194)
61. Singhal P., Naswa S., Marfatia Y. S., Pregnancy and sexually transmitted viral infections. Indian Journal of Sexually Transmitted Diseases 2009 30 2 71 78 2-s2.0-77953406779 10.4103/0253-7184.62761
62. Brown Z. A., Wald A., Morrow R. A., Selke S., Zeh J., Corey L., Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. The Journal of the American Medical Association 2003 289 2 203 209 2-s2.0-0037425558 10.1001/jama.289.2.203 (Pubitemid 36068708)
63. Westhoff G. L., Little S. E., Caughey A. B., Herpes simplex virus and pregnancy: a review of the management of antenatal and peripartum herpes infections. Obstetrical and Gynecological Survey 2011 66 10 629 638 10.1097/OGX.0b013e31823983ec
64. Cérbulo-Vázquez A., Valdés-Ramos R., Santos-Argumedo L., Activated umbilical cord blood cells from pre-term and term neonates express CD69 and synthesize IL-2 but are unable to produce IFN- γ Archives of Medical Research 2003 34 2 100 105 2-s2.0-17644397745 10.1016/S0188-4409(03) 00018-3 (Pubitemid 36434065)
65. Fischer G. W., Ottolini M. G., Mond J. J., Prospects for vaccines during pregnancy and in the newborn period. Clinics in Perinatology 1997 24 1 231 249 2-s2.0-0030992379 (Pubitemid 27180785)
66. Englund J., Glezen W. P., Piedra P. A., Maternal immunization against viral disease. Vaccine 1998 16 14-15 1456 1463 2-s2.0-0032147233 10.1016/S0264-410X(98)00108-X (Pubitemid 28364684)
67. Holmlund E., Nohynek H., Quiambao B., Ollgren J., Käyhty H., Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 2011 29 28 4565 4575 2-s2.0-79958160311 10.1016/j.vaccine.2011.04.068
68. Schleiss M. R., Lacayo J. C., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J. D., Smith J. F., Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. Journal of Infectious Diseases 2007 195 6 789 798 2-s2.0-33847637628 10.1086/511982 (Pubitemid 46363923)
69. Wilks A. B., Christian E. C., Seaman M. S., Sircar P., Carville A., Gomez C. E., Esteban M., Pantaleo G., Barouch D. H., Letvin N. L., Permar S. R., Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. Journal of Immunology 2010 185 11 7097 7106 2-s2.0-78650670121 10.4049/jimmunol.1002751
70. Munoz F. M., Englund J. A., Cheesman C. C., Maccato M. L., Pinell P. M., Nahm M. H., Mason E. O., Kozinetz C. A., Thompson R. A., Glezen W. P., Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001 20 5-6 826 837 2-s2.0-0035852334 10.1016/S0264-410X(01) 00397-8 (Pubitemid 34015822)
71. Bagarazzi M. L., Boyer J. D., Javadian M. A., Chattergoon M. A., Shah A. R., Cohen A. D., Bennett M. K., Ciccarelli R. B., Ugen K. E., Weiner D. B., Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. Journal of Infectious Diseases 1999 180 4 1351 1355 2-s2.0-0033389282 10.1086/314978 (Pubitemid 30070227)
72. McCluskie M. J., Weeratna R. D., Payette P. J., Davis H. L., Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunology and Medical Microbiology 2002 32 3 179 185 2-s2.0-0037128135 10.1016/S0928-8244(01)00305-4 (Pubitemid 34270507)
73. BenMohamed L., Krishnan R., Auge C., Primus J. F., Diamond D. J., Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002 106 1 113 121 2-s2.0-0036241804 10.1046/j.1365-2567.2002.01396.x (Pubitemid 34437884)
74. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., Druilhe P., Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. European Journal of Immunology 2002 32 8 2274 2281 10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C (Pubitemid 34965890)
75. Chentoufi A. A., BenMohamed L., Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. Future Virology 2010 5 5 525 528 2-s2.0-77957317515 10.2217/fvl.10.44
76. + cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. Journal of Virology 2008 82 23 11792 11802 2-s2.0-56449115358 10.1128/JVI.00692-08
77. Dasgupta G., Chentoufi A. A., Kalantari M., Falatoonzadeh P., Chun S., Lim C. H., Felgner P. L., Davies D. H., BenMohamed L., Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. Journal of Virology 2012 86 8 4358 4369 10.1128/JVI.07107-11
78. Dasgupta G., Nesburn A. B., Wechsler S. L., BenMohamed L., Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiology 2010 5 1 1 4 2-s2.0-75949090236 10.2217/fmb.09.101
79. Dervillez X., Gottimukkala C., Kabbara K. W., Nguyen C., Badakhshan T., Kim S. M., Nesburn A. B., Wechsler S. L., Benmohamed L., Future of an "asymptomatic" T-cell epitope-based therapeutic herpes simplex vaccine. Future Virology 2012 7 4 371 378 10.2217/fvl.12.22
80. Hayday A., Viney J. L., The ins and outs of body surface immunology. Science 2000 290 5489 97 100 2-s2.0-0034613273 10.1126/science.290.5489.97
81. Knop E., Knop N., The role of eye-associated lymphoid tissue in corneal immune protection. Journal of Anatomy 2005 206 3 271 285 2-s2.0-15844363836 10.1111/j.1469-7580.2005.00394.x (Pubitemid 40424847)
82. + effector T cells during ocular herpes infection. Journal of Virology 2007 81 14 7647 7661 2-s2.0-34447263785 10.1128/JVI.00294-07 (Pubitemid 47047850)
83. Nesburn A. B., Ramos T. V., Zhu X., Asgarzadeh H., Nguyen V., Benmohamed L., Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 2005 23 7 873 883 2-s2.0-10444280011 10.1016/j.vaccine.2004.08.019 (Pubitemid 39643174)
84. Bettahi I., Nesburn A. B., Yoon S., Zhang X., Mohebbi A., Sue V., Vanderberg A., Wechsler S. L., BenMohamed L., Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Investigative Ophthalmology and Visual Science 2007 48 10 4643 4653 2-s2.0-35748930569 10.1167/iovs.07-0356 (Pubitemid 351260982)
85. + Tc1 responses and protect against ocular infection. Journal of Virology 2005 79 24 15289 15301 2-s2.0-29744451544 10.1128/JVI.79.24.15289- 15301.2005 (Pubitemid 43032311)
86. Zhu X., Ramos T. V., Gras-Masse H., Kaplan B. E., BenMohamed L., Lipopeptide epitopes extended by an NE-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. European Journal of Immunology 2004 34 11 3102 3114 2-s2.0-9244235974 10.1002/eji.200425166 (Pubitemid 39549389)
87. Knop E., Knop N., Eye-associated lymphoid tissue (EALT) is continuously spread throughout the ocular surface from the lacrimal gland to the lacrimal drainage system. Ophthalmologe 2003 100 11 929 942 2-s2.0-0344394309 10.1007/s00347-003-0936-6 (Pubitemid 37498912)
88. Montgomery P. C., Rockey J. H., Majumdar A. S., Parameters influencing the expression of IgA antibodies in tears. Investigative Ophthalmology and Visual Science 1984 25 3 369 373 (Pubitemid 14164790)
89. Lathers D. M. R., Gill R. F., Montgomery P. C., Inductive pathways leading to rat tear IgA antibody responses. Investigative Ophthalmology and Visual Science 1998 39 6 1005 1011 2-s2.0-0004285458 (Pubitemid 28196686)
90. Saitoh-Inagawa W., Hiroi T., Yanagita M., Iijima H., Uchio E., Ohno S., Aoki K., Kiyono H., Unique characteristics of lacrimal glands as a part of mucosal immune network: high frequency of IgA-committed B-1 cells and NK1.1+ α β T cells. Investigative Ophthalmology and Visual Science 2000 41 1 138 144 2-s2.0-0033988794 (Pubitemid 30036560)
91. Knop N., Knop E., Ultrastructural anatomy of CALT follicles in the rabbit reveal characteristics of M-cells, germinal centres and high endothelial venules. Journal of Anatomy 2005 207 4 409 426 2-s2.0-26944481070 10.1111/j.1469-7580.2005.00470.x (Pubitemid 41479544)
92. Richards C. M., Case R., Hirst T. R., Hill T. J., Williams N. A., Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. Journal of Virology 2003 77 12 6692 6699 2-s2.0-0038280048 10.1128/JVI.77.12.6692-6699.2003 (Pubitemid 36666863)
93. Byun Y., Ohmura M., Fujihashi K., Yamamoto S., McGhee J. R., Udaka S., Kiyono H., Takeda Y., Kohsaka T., Yuki Y., Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 2001 19 15-16 2061 2070 2-s2.0-0035961454 10.1016/S0264-410X(00)00411-4 (Pubitemid 32178356)
94. Olszewska W., Erume J., Ripley J., Steward M. W., Partidos C. D., Immune responses and protection induced by mucosal and systemic immunisation with recombinant measles nucleoprotein in a mouse model of measles virus-induced encephalitis. Archives of Virology 2001 146 2 293 302 2-s2.0-0035095930 10.1007/s007050170176 (Pubitemid 32258299)
95. Gallichan W. S., Woolstencroft R. N., Guarasci T., McCluskie M. J., Davis H. L., Rosenthal K. L., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. Journal of Immunology 2001 166 5 3451 3457 2-s2.0-0035284751 (Pubitemid 33117348)
96. Parr E. L., Parr M. B., Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 1999 98 4 639 645 2-s2.0-0033407142 10.1046/j.1365-2567.1999.00909.x (Pubitemid 30005348)
97. Knop E., Knop N., Brewitt H., Dry eye disease as a complex dysregulation of the functional anatomy of the ocular surface. New impulses to understanding dry eye disease. Ophthalmologe 2003 100 11 917 928 2-s2.0-0345095350 10.1007/s00347-003-0935-7 (Pubitemid 37498911)
98. Kuper C. F., Koornstra P. J., Hameleers D. M. H., Biewenga J., Spit B. J., Duijvestijn A. M., van Breda Vriesman P. J. C., Sminia T., The role of nasopharyngeal lymphoid tissue. Immunology Today 1992 13 6 219 224 2-s2.0-0026578979
99. + T-cell responses induced following topical ocular or intranasal immunization. Clinical and Vaccine Immunology 2010 17 3 342 353 2-s2.0-77649240395 10.1128/CVI.00347-09
100. Gebhardt T., Wakim L. M., Eidsmo L., Reading P. C., Heath W. R., Carbone F. R., Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nature Immunology 2009 10 5 524 530 2-s2.0-65249134069 10.1038/ni.1718
101. + T (RM) cells providing global skin immunity. Nature 2012 483 7388 227 231 10.1038/nature10851
102. + T cells. Nature 2011 477 7363 216 219 10.1038/nature10339
103. Stevens D. A., Merigan T. C., Approaches to the control of viral infections in man. Rational Drug Therapy 1971 5 9 1 5 2-s2.0-0015121934
104. Laycock K. A., Lee S. F., Brady R. H., Pepose J. S., Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Investigative Ophthalmology and Visual Science 1991 32 10 2741 2746 2-s2.0-0025751630
105. Sawtell N. M., Thompson R. L., Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. Journal of Virology 1992 66 4 2157 2169 2-s2.0-0026583838
106. Sawtell N. M., Thompson R. L., Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. Journal of Virology 1992 66 4 2150 2156 2-s2.0-0026608638
107. + T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae 2011 2, article 5 10.1186/2042-4280-2-5
108. Bonneau R. H., Zimmerman K. M., Ikeda S. C., Jones B. C., Differential effects of stress-induced adrenal function on components of the herpes simplex virus-specific memory cytotoxic T-lymphocyte response. Journal of Neuroimmunology 1998 82 2 191 199 2-s2.0-0031893674 10.1016/S0165-5728(97)00200- 2 (Pubitemid 28179922)
109. + T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells. Journal of Immunology 2011 186 1 183 194 2-s2.0-79251549773 10.4049/jimmunol.1001737
110. Elftman M. D., Hunzeker J. T., Mellinger J. C., Bonneau R. H., Norbury C. C., Truckenmiller M. E., Stress-induced glucocorticoids at the earliest stages of herpes simplex virus-1 infection suppress subsequent antiviral immunity, implicating impaired dendritic cell function. Journal of Immunology 2010 184 4 1867 1875 2-s2.0-77949881218 10.4049/jimmunol.0902469
111. Sheridan J. F., Feng N., Bonneau R. H., Allen C. M., Huneycutt B. S., Glaser R., Restraint stress differentially affects anti-viral cellular and humoral immune responses in mice. Journal of Neuroimmunology 1991 31 3 245 255 2-s2.0-0026057853 10.1016/0165-5728(91)90046-A
112. + T cell control of latent herpes simplex virus type 1 infections. Journal of Immunology 2007 179 1 322 328 2-s2.0-34250873275 (Pubitemid 46986548)
113. Chentoufi A. A., Dervillez X., Dasgupta G., Nguyen C., Kabbara K. W., Jiang X., Nesburn A. B., Wechsler S. L., BenMohamed L., The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells. Viral Immunology 2012 25 3 204 215 10.1089/vim.2011.0091
114. + T
115. Veiga-Parga T., Suryawanshi A., Rouse B. T., Controlling viral immuno-inflammatory lesions by modulating aryl hydrocarbon receptor signaling. PLoS Pathogens 2011 7 12 e1002427 10.1371/journal.ppat.1002427
116. Suryawanshi A., Veiga-Parga T., Rajasagi N. K., Reddy P. B. J., Sehrawat S., Sharma S., Rouse B. T., Role of il-17 and th17 cells in herpes simplex virus-induced corneal immunopathology. Journal of Immunology 2011 187 4 1919 1930 10.4049/jimmunol.1100736
117. Reddy P. B. J., Sehrawat S., Suryawanshi A., Rajasagi N. K., Mulik S., Hirashima M., Rouse B. T., Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. Journal of Immunology 2011 187 11 5745 5755 10.4049/jimmunol.1102105
118. Perng G. C., Esmaili D., Slanina S. M., Yukht A., Ghiasi H., Osorio N., Mott K. R., Maguen B., Jin L., Nesburn A. B., Wechsler S. L., Three herpes simplex virus type 1 latency-associated transcript mutants with distinct and asymmetric effects on virulence in mice compared with rabbits. Journal of Virology 2001 75 19 9018 9028 2-s2.0-0034844016 10.1128/JVI.75.19.9018-9028.2001 (Pubitemid 32851906)
119. Inman M., Perng G. C., Henderson G., Ghiasi H., Nesburn A. B., Wechsler S. L., Jones C., Region of herpes simplex virus type 1 latency-associated transcript sufficient for wild-type spontaneous reactivation promotes cell survival in tissue culture. Journal of Virology 2001 75 8 3636 3646 2-s2.0-0035087392 10.1128/JVI.75.8.3636-3646.2001 (Pubitemid 32246373)
120. Perng G. C., Jones C., Ciacci-Zanella J., Stone M., Henderson G., Yukht A., Slanina S. M., Hofman F. M., Ghiasi H., Nesburn A. B., Wechsler S. L., Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000 287 5457 1500 1503 2-s2.0-0034712014 10.1126/science.287.5457.1500 (Pubitemid 30127146)
121. Jiang X., Chentoufi A. A., Hsiang C., Carpenter D., Osorio N., BenMohamed L., Fraser N. W., Jones C., Wechsler S. L., The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing. Journal of Virology 2011 85 5 2325 2332 2-s2.0-79551719108 10.1128/JVI.01791-10
122. + T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. Journal of Virology 2011 85 9 4184 4197 2-s2.0-79955444899 10.1128/JVI.02290-10
123. + T cell exhaustion and promotes maintenance of herpes simplex virus 1 latency. Journal of Immunology 2010 184 1 277 286 2-s2.0-73949138471 10.4049/jimmunol.0902373
124. Sehrawat S., Reddy P. B., Rajasagi N., Suryawanshi A., Hirashima M., Rouse B. T., Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathogens 2010 6 5 e1000882 2-s2.0-77955962823 10.1371/journal.ppat.1000882
125. Wherry E. J., T cell exhaustion. Nature Immunology 2011 12 6 492 499 2-s2.0-79956077563 10.1038/ni.2035
126. Allen S. J., Mott K. R., Zandian M., Ghiasi H., Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice. Journal of Virology 2010 84 23 12315 12324 2-s2.0-78049511214 10.1128/JVI.01600-10
127. Day C. L., Kaufmann D. E., Kiepiela P., Brown J. A., Moodley E. S., Reddy S., Mackey E. W., Miller J. D., Leslie A. J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E. J., Coovadia H. M., Goulder P. J. R., Klenerman P., Ahmed R., Freeman G. J., Walker B. D., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006 443 7109 350 354 2-s2.0-33748947326 10.1038/nature05115 (Pubitemid 44435155)
128. + T cells in latently HSV-1-infected human trigeminal ganglia. Journal of NeuroVirology 2012 18 1 62 68 10.1007/s13365-011-0067-9
129. Held K., Junker A., Dornmair K., Meinl E., Sinicina I., Brandt T., Theil D., Derfuss T., Expression of herpes simplex virus 1-encoded microRNAs in human trigeminal ganglia and their relation to local T-cell infiltrates. Journal of Virology 2011 85 19 9680 9685 10.1128/JVI.00874-11
130. + T cells in latently HSV-1-infected human trigeminal ganglia. Journal of NeuroVirology 2012 18 1 62 68 10.1007/s13365-011-0067-9
131. Held K., Derfuss T., Control of HSV-1 latency in human trigeminal ganglia-current overview. Journal for Neurovirology 2011 17 6 518 527 10.1007/s13365-011-0063-0
132. + T cells. Journal of medical virology 2010 82 11 1917 1920 2-s2.0-79952116937
133. van Velzen M., Laman J. D., KleinJan A., Poot A., Osterhaus A. D. M. E., Verjans G. M. G. M., Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. Journal of Immunology 2009 183 4 2456 2461 2-s2.0-70149094176 10.4049/jimmunol.0900890
134. Sheridan B. S., Cherpes T. L., Urban J., Kalinski P., Hendricks R. L., Reevaluating the CD8 T-Cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes. Journal of Virology 2009 83 5 2237 2245 2-s2.0-60049097877 10.1128/JVI.01699-08
135. Liu T., Khanna K. M., Chen X., Fink D. J., Hendricks R. L., CD8+ T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. Journal of Experimental Medicine 2000 191 9 1459 1466 2-s2.0-0034192426 10.1084/jem.191.9.1459 (Pubitemid 30257343)
136. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008 322 5899 268 271 2-s2.0-53749095611 10.1126/science.1164164
137. Liu T., Khanna K. M., Carriere B. N., Hendricks R. L., Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. Journal of Virology 2001 75 22 11178 11184 2-s2.0-0034764062 10.1128/JVI.75.22.11178-11184.2001 (Pubitemid 33031584)
138. + T cells maintain HSV-1 latency. Immunologic Research 2006 36 1-3 119 126 2-s2.0-33947144288 (Pubitemid 46398586)
139. Khanna K. M., Lepisto A. J., Hendricks R. L., Immunity to latent viral infection: many skirmishes but few fatalities. Trends in Immunology 2004 25 5 230 234 2-s2.0-4043126793 10.1016/j.it.2004.02.010 (Pubitemid 38501668)
140. Rock D. L., Nesburn A. B., Ghiasi H., Ong J., Lewis T. L., Lokensgard J. R., Wechsler S. L., Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. Journal of Virology 1987 61 12 3820 3826 2-s2.0-0023502309 (Pubitemid 18011480)
141. Stevens J. G., Wagner E. K., Devi-Rao G. B., RNA complementary to a herpesvirus α gene mRNA is prominent in latently infected neurons. Science 1987 235 4792 1056 1059 2-s2.0-0023140228 (Pubitemid 17049754)
142. Perng G. C., Dunkel E. C., Geary P. A., Slanina S. M., Ghiasi H., Kaiwar R., Nesburn A. B., Wechsler S. L., The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. Journal of Virology 1994 68 12 8045 8055 2-s2.0-0028138560 (Pubitemid 24362693)
143. Trousdale M. D., Steiner I., Spivack J. G., Deshmane S. L., Brown S. M., MacLean A. R., Subak-Sharpe J. H., Fraser N. W., In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. Journal of Virology 1991 65 12 6989 6993 2-s2.0-0025789629
144. Leib D. A., Bogard C. L., Kosz-Vnenchak M., Hicks K. A., Coen D. M., Knipe D. M., Schaffer P. A., A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. Journal of Virology 1989 63 7 2893 2900 2-s2.0-0024312746 (Pubitemid 19156006)
145. Deshpande S. P., Kumaraguru U., Rouse B. T., Why do we lack an effective vaccine against herpes simplex virus infections? Microbes and Infection 2000 2 8 973 978 2-s2.0-0033925360 10.1016/S1286-4579(00)00339-7 (Pubitemid 30483193)
146. Pivetti-Pezzi P., Accorinti M., Colabelli-Gisoldi R. A. M., Pirraglia M. P., Sirianni M. C., Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea 1999 18 1 47 51 2-s2.0-0032900296 (Pubitemid 29014004)
147. Corey L., Langenberg A. G. M., Ashley R., Sekulovich R. E., Izu A. E., Douglas J. M. Jr., Handsfield H. H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A. A., Leone P., Dekker C. L., Burke R. L., Leong W. P., Straus S. E., Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. The Journal of the American Medical Association 1999 282 4 331 340 2-s2.0-0033612702 10.1001/jama.282.4.331 (Pubitemid 29350487)
148. Krause P. R., Straus S. E., Herpesvirus vaccines. Development, controversies, and applications. Infectious Disease Clinics of North America 1999 13 1 61 81 10.1016/S0891-5520(05)70043-X (Pubitemid 29164365)
149. Sin J. I., Ayyavoo V., Boyer J., Kim J., Ciccarelli R. B., Weiner D. B., Protective immune correlates can segregate by vaccine type in a murine herpes model system. International Immunology 1999 11 11 1763 1773 2-s2.0-0032716322 10.1093/intimm/11.11.1763 (Pubitemid 29533091)
150. Friedman H. M., Hartley C., Corey L., Langenberg A. G. M., Burke R. L., Straus S., Mascola J. R., Immunologic strategies for herpes vaccination. The Journal of the American Medical Association 2000 283 6 746 747
151. BenMohamed L., Wechsler S. L., Nesburn A. B., Lipopeptide vaccines-yesterday, today, and tomorrow. The Lancet Infectious Diseases 2002 2 7 425 431 2-s2.0-0036295173 10.1016/S1473-3099(02)00318-3 (Pubitemid 34693260)
152. Koelle D. M., Ghiasi H., Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Current Eye Research 2005 30 11 929 942 2-s2.0-31544482423 10.1080/02713680500313153 (Pubitemid 43154687)
153. + cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. Journal of Immunology 2008 180 1 426 437 2-s2.0-40449086460
154. Russell M. W., Immunization for protection of the reproductive tract: a review. American Journal of Reproductive Immunology 2002 47 5 265 268 2-s2.0-0036239761 10.1034/j.1600-0897.2002.01099.x (Pubitemid 34464186)
155. Kaul R., Pettengell C., Sheth P. M., Sunderji S., Biringer A., MacDonald K., Walmsley S., Rebbapragada A., The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. Journal of Reproductive Immunology 2008 77 1 32 40 2-s2.0-38149074165 10.1016/j.jri.2007. 02.002
156. MasCasullo V., Fam E., Keller M. J., Herold B. C., Role of mucosal immunity in preventing genital herpes infection. Viral Immunology 2005 18 4 595 606 2-s2.0-29844454067 10.1089/vim.2005.18.595 (Pubitemid 43038525)
157. Milligan G. N., Dudley-McClain K. L., Chu C. F., Young C. G., Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 2004 318 2 507 515 2-s2.0-1242328735 10.1016/j.virol.2003.10.010 (Pubitemid 38224294)
158. Kwant A., Rosenthal K. L., Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004 22 23-24 3098 3104 2-s2.0-3843066750 10.1016/j.vaccine.2004. 01.059 (Pubitemid 39037213)
159. Hamajima K., Hoshino Y., Xin K. Q., Hayashi F., Tadokoro K., Okuda K., Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clinical Immunology 2002 102 1 12 18 2-s2.0-0036150480 10.1006/clim.2001.5141 (Pubitemid 34095219)
160. Gallichan W. S., Rosenthal K. L., Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. Journal of Infectious Diseases 1998 177 5 1155 1161 2-s2.0-0031899819 (Pubitemid 28194251)
161. Koelle D. M., Vaccines for herpes simplex virus infections. Current Opinion in Investigational Drugs 2006 7 2 136 141 2-s2.0-32544452998 (Pubitemid 43230909)
162. Bernstein D., Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Review of Vaccines 2005 4 5 615 627 2-s2.0-27444436352 10.1586/14760584.4.5.615 (Pubitemid 41530586)
163. Hoshino Y., Dalai S. K., Wang K., Pesnicak L., Lau T. Y., Knipe D. M., Cohen J. I., Straus S. E., Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 2005 79 1 7 410 418 (Pubitemid 39648394)
164. Bossi P., Genital herpes: epidemiology, transmission, clinic, asymptomatic viral excretion, impact on other sexually transmitted diseases, prevention, and treatment. Annales de Dermatologie et de Venereologie 2002 129 4 477 493 2-s2.0-0036273490 (Pubitemid 34606377)
165. + T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals. Journal of General Virology 2004 85 8 2139 2147 2-s2.0-4043081295 10.1099/vir.0.79978-0 (Pubitemid 39172074)
166. Celum C. L., The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004 11 supplement 1 36A 45A 2-s2.0-1942499496 (Pubitemid 38529333)
167. + T cell help. Journal of Immunology 1991 147 12 4069 4073 2-s2.0-0026327141
168. Kast W. M., Melief C. J. M., In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunology Letters 1991 30 2 229 232 2-s2.0-0025945836 10.1016/0165-2478(91)90030-E
169. Schulz M., Zinkernagel R. M., Hengartner H., Peptide-induced antiviral protection by cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America 1991 88 3 991 993 2-s2.0-0026034957 10.1073/pnas.88.3.991 (Pubitemid 21916150)
170. Kastrup I. B., Stevanovic S., Arsequell G., Valencia G., Zeuthen J., Rammensee H. G., Elliott T., Haurum J. S., Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 2000 56 2 129 135 2-s2.0-0033864113 10.1034/j.1399-0039.2000.560203.x (Pubitemid 30621278)
171. BenMohamed L., Krishnan R., Longmate J., Auge C., Low L., Primus J., Diamond D. J., Induction of CTL response by a minimal epitope vaccine in HLA A-0201/Dr1 transgenic mice: dependence on HLA class II restricted T(h) response. Human Immunology 2000 61 8 764 779 2-s2.0-0033812637 10.1016/S0198-8859(00) 00139-7
172. BenMohamed L., Thomas A., Bossus M., Brahimi K., Wubben J., Gras-Masse H., Druilhe P., High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 2000 18 25 2843 2855 2-s2.0-0034659607 (Pubitemid 30254472)
173. Daubersies P., Thomas A. W., Millet P., Brahimi K., Langermans J. A. M., Ollomo B., BenMohamed L., Slierendregt B., Eling W., van Belkum A., Dubreuil G., Meis J. F. G. M., Guerin-Marchand C., Cayphas S., Cohen J., Gras-Masse H., Druilhe P., Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature Medicine 2000 6 11 1258 1263
174. Nesburn A. B., Burke R. L., Ghiasi H., Slanina S. M., Wechsler S. L., Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 1998 252 1 200 209 2-s2.0-0032488254 10.1006/viro.1998.9454 (Pubitemid 28564145)
175. Nesburn A. B., Burke R. L., Gbiasi H., Slanina S. M., Wechsler S. L., A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Investigative Ophthalmology and Visual Science 1998 39 7 1163 1170 2-s2.0-0031862117 (Pubitemid 28247350)
176. Nesburn A. B., Slanina S., Burke R. L., Ghiasi H., Bahri S., Wechsler S. L., Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. Journal of Virology 1998 72 10 7715 7721 2-s2.0-0031719012 (Pubitemid 28421761)
177. Powell M. F., Eastman D. J., Lim A., Lucas C., Peterson M., Vennari J., Weissburg R. P., Wrin T., Kensil C. R., Newman M. J., Nunberg J., Cleland J. L., Gregory T. J., Berman P. W., Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Research and Human Retroviruses 1995 11 2 203 209 2-s2.0-0029141671
178. Gupta R. K., Siber G. R., Adjuvants for human vaccines. Current status, problems and future prospects. Vaccine 1995 13 14 1263 1276 2-s2.0-0028884598 10.1016/0264-410X(95)00011-O
179. + T lymphocyte activation. European Journal of Immunology 2000 30 11 3256 3265 10.1002/1521-4141(200011)30:11<3256::AID- IMMU3256>3.0.CO;2-H
180. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Bossus M., Thomas A., Druilhe P., Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. European Journal of Immunology 1997 27 5 1242 1253 2-s2.0-0030959609 (Pubitemid 27197230)
181. Bourgault I., Chirat F., Tartar A., Levy J. P., Guillet J. G., Venet A., Simian immunodeficiency virus as a model for vaccination against HIV: induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. Journal of Immunology 1994 152 5 2530 2537 2-s2.0-0028316559 (Pubitemid 24097946)
182. Gahéry-Ségard H., Pialoux G., Charmeteau B., Sermet S., Poncelet H., Raux M., Tartar R., Lévy J. P., Gras-Masse H., Guillet J. G., Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. Journal of Virology 2000 74 4 1694 1703 2-s2.0-0342647378 10.1128/JVI.74.4.1694-1703.2000 (Pubitemid 30434025)
183. Gras-Masse H., Chemoselective ligation and antigen vectorization. Biologicals 2001 29 3-4 183 188 2-s2.0-0035697512 10.1006/biol.2001.0304 (Pubitemid 34093639)
184. Gras-Masse H., Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations. Molecular Immunology 2001 38 6 423 431 2-s2.0-0035652261 10.1016/S0161-5890(01) 00078-5 (Pubitemid 34008472)
185. Livingston B. D., Crimi C., Grey H., Ishioka G., Chisari F. V., Fikes J., Grey H., Chesnut R. W., Sette A., The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. Journal of Immunology 1997 159 3 1383 1392 2-s2.0-0031204408 (Pubitemid 127484117)
186. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J. G., Gomard E., Tartar A., Levy J. P., Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant: immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. Journal of Immunology 1992 149 10 3416 3422 2-s2.0-0026471201
187. Pialoux G., Gahéry-Ségard H., Sermet S., Poncelet H., Fournier S., Gérard L., Tartar A., Gras-Masse H., Levy J. P., Guillet J. G., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001 15 10 1239 1249 2-s2.0-0035816391 10.1097/00002030- 200107060-00005 (Pubitemid 32592356)
188. Sauzet J. P., Deprez B., Martinon F., Guillet J. G., Gras-Masse H., Gomard E., Long-lasting anti viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 1995 13 14 1339 1345 2-s2.0-0028972123 10.1016/0264-410X(94)00087-4
189. Schild H., Deres K., Wiesmuller K. H., Jung G., Rammensee H. G., Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. European Journal of Immunology 1991 21 11 2649 2654 2-s2.0-0026091287
190. Seth A., Yasutomi Y., Jacoby H., Callery J. C., Kaminsky S. M., Koff W. C., Nixon D. F., Letvin N. L., Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Research and Human Retroviruses 2000 16 4 337 343 2-s2.0-0034052914 10.1089/088922200309214 (Pubitemid 30132088)
191. Tsunoda I., Sette A., Fujinami R. S., Oseroff C., Ruppert J., Dahlberg C., Southwood S., Arrhenius T., Kuang L. Q., Kubo R. T., Chesnut R. W., Ishioka G. Y., Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine 1999 17 7-8 675 685 2-s2.0-0033605091 10.1016/S0264-410X(98)00250-3 (Pubitemid 29074721)
192. Vitiello A., Ishioka G., Grey H. M., Rose R., Farness P., LaFond R., Yuan L., Chisari F. V., Furze J., Bartholomeuz R., Chesnut R. W., Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. Journal of Clinical Investigation 1995 95 1 341 349 2-s2.0-0028876917
193. Diamond D. J., York J., Sun J. Y., Wright C. L., Forman S. J., Development of a candidate HLA A-0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997 90 5 1751 1767 2-s2.0-0030928128 (Pubitemid 27377285)
194. BenMohamed L., Thomas A., Druilhe P., Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and Immunity 2004 72 8 4376 4384 2-s2.0-3342994925 10.1128/IAI.72.8.4376-4384.2004 (Pubitemid 38989293)
195. Launay O., Durier C., Desaint C., Silbermann B., Jackson A., Pialoux G., Bonnet B., Poizot-Martin I., Gonzalez-Canali G., Cuzin L., Figuereido S., Surenaud M., Ben Hamouda N., Gahery H., Choppin J., Salmon D., Guérin C., Bourgault Villada I., Guillet J. G., Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PloS ONE 2007 2 1, article e725 2-s2.0-77949320259
196. Livingston B., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., Sette A., A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. Journal of Immunology 2002 168 11 5499 5506 2-s2.0-0036604410 (Pubitemid 34556128)
197. + IFN- γ and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. Journal of Immunology 2002 168 12 6189 6198 2-s2.0-0037097764 (Pubitemid 34620038)
198. Belyakov I. M., Berzofsky J. A., Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004 20 3 247 253 2-s2.0-1642381854 10.1016/S1074-7613(04)00053-6 (Pubitemid 38388227)
199. Berzofsky J. A., Ahlers J. D., Derby M. A., Pendleton C. D., Arichi T., Belyakov I. M., Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunological Reviews 1999 170 151 172 2-s2.0-0032869689 10.1111/j.1600-065X. 1999.tb01336.x (Pubitemid 29490752)
200. Gherardi M. M., Pérez-Jiménez E., Nájera J. L., Esteban M., Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus ankara boost immunization schedule. Journal of Immunology 2004 172 10 6209 6220 2-s2.0-2442517281 (Pubitemid 38621227)
201. Tengvall S., Lundqvist A., Eisenberg R. J., Cohen G. H., Harandi A. M., Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. Journal of Virology 2006 80 11 5283 5291 2-s2.0-33646744394 10.1128/JVI.02013-05
202. Rosenthal K. L., Gallichan W. S., Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Seminars in Immunology 1997 9 5 303 314 2-s2.0-0031251985 10.1006/smim.1997.0086 (Pubitemid 28077728)
203. Corey L., The current trend in genital herpes: progress in prevention. Sexually Transmitted Diseases 1994 21 2 S38 S44 2-s2.0-0028292947 (Pubitemid 24130346)
204. Straus S. E., Wald A., Kost R. G., McKenzie R., Langenberg A. G. M., Hohman P., Lekstrom J., Cox E., Nakamura M., Sekulovich R., Izu A., Dekker C., Corey L., Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. Journal of Infectious Diseases 1997 176 5 1129 1134 2-s2.0-16944362192 (Pubitemid 27460974)
205. Zheng M., Conrady C. D., Ward J. M., Bryant-Hudson K. M., Carr D. J. J., Comparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites. Journal of Virology 2012 86 13 7454 7458 10.1128/JVI.00702-12
206. Hendricks R. L., Epstein R. J., Tumpey T., The effect of cellular immune tolerance to HSV-1 antigens on the immunopathology fo HSV-1 keratitis. Investigative Ophthalmology and Visual Science 1989 30 1 105 115 2-s2.0-0024559116 (Pubitemid 19039886)
207. Tumpey T. M., Chen S. H., Oakes J. E., Lausch R. N., Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. Journal of Virology 1996 70 2 898 904 2-s2.0-0030045764 (Pubitemid 26029006)
208. Shimeld C., Whiteland J. L., Nicholls S. M., Easty D. L., Hill T. J., Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease. Journal of General Virology 1996 77 5 977 985 2-s2.0-0029876828 (Pubitemid 26142332)
209. Hendricks R. L., Tumpey T. M., Concurrent regeneration of T lymphocytes and susceptibility to HSV-1 corneal stromal disease. Current Eye Research 1991 10, supplement 47 53 2-s2.0-0025762990
210. Hendricks R. L., Weber P. C., Taylor J. L., Koumbis A., Tumpey T. M., Glorioso J. C., Endogenously produced interferon α protects mice from herpes simplex virus type 1 corneal disease. Journal of General Virology 1991 72 7 1601 1610 2-s2.0-0025768265
211. Newell C. K., Martin S., Sendele D., Mercadal C. M., Rouse B. T., Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. Journal of Virology 1989 63 2 769 775 2-s2.0-0024552765 (Pubitemid 19057244)
212. Thomas J., Gangappa S., Kanangat S., Rouse B. T., On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. Journal of Immunology 1997 158 3 1383 1391 2-s2.0-0031066764 (Pubitemid 127469965)
213. Metcalf J. F., Hamilton D. S., Reichert R. W., Herpetic keratitis in athymic (nude) mice. Infection and Immunity 1979 26 3 1164 1171 2-s2.0-0018667229 (Pubitemid 10212982)
214. Russell R. G., Nasisse M. P., Larsen H. S., Rouse B. T., Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Investigative Ophthalmology and Visual Science 1984 25 8 938 944 2-s2.0-0021212101 (Pubitemid 14055891)
215. Hendricks R. L., Janowicz M., Tumpey T. M., Critical role of corneal Langerhans cells in the CD4- but not CD8-mediated immunopathology in herpes simplex virus-1-infected mouse corneas. Journal of Immunology 1992 148 8 2522 2529 2-s2.0-0026597908
216. Hendricks R. L., Tumpey T. M., Finnegan A., IFN- γ and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. Journal of Immunology 1992 149 9 3023 3028 2-s2.0-0026783734
217. Niemialtowski M. G., Rouse B. T., Phenotypic and functional studies on ocular T cells during herpetic infections of the eye. Journal of Immunology 1992 148 6 1864 1870 2-s2.0-0026535405
218. Niemialtowski M. G., Rouse B. T., Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis. Journal of Immunology 1992 149 9 3035 3039 2-s2.0-0026758280
219. Tang Q., Chen W., Hendricks R. L., Proinflammatory functions of IL-2 in herpes simplex virus corneal infection. Journal of Immunology 1997 158 3 1275 1283 2-s2.0-0031066919 (Pubitemid 127469952)
220. Tang Q., Hendricks R. L., Interferon γ regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas. Journal of Experimental Medicine 1996 184 4 1435 1447 2-s2.0-0029911156 10.1084/jem.184.4.1435 (Pubitemid 26354699)
221. Chen H., Hendricks R. L., B7 costimulatory requirements of T cells at an inflammatory site. Journal of Immunology 1998 160 10 5045 5052 2-s2.0-0032525050 (Pubitemid 28215341)
222. Jayaraman S., Heiligenhaus A., Rodriguez A., Soukiasian S., Dorf M. E., Foster C. S., Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells. Journal of Immunology 1993 151 10 5777 5789 2-s2.0-0027384275 (Pubitemid 23332387)
223. Tumpey T. M., Cheng H., Yan X. T., Oakes J. E., Lausch R. N., Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. Journal of Leukocyte Biology 1998 63 4 486 492 2-s2.0-0031958356 (Pubitemid 28163189)
224. Tumpey T. M., Elner V. M., Chen S. H., Oakes J. E., Lausch R. N., Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. Journal of Immunology 1994 153 5 2258 2265 2-s2.0-0027968670 (Pubitemid 24256698)
225. Divito S. J., Hendricks R. L., Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Investigative Ophthalmology and Visual Science 2008 49 4 1488 1495 2-s2.0-45549090762 10.1167/iovs.07-1107
226. Koelle D. M., Reymond S. N., Chen H., Kwok W. W., McClurkan C., Gyaltsong T., Petersdorf E. W., Rotkis W., Talley A. R., Harrison D. A., Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. Journal of Virology 2000 74 23 10930 10938 2-s2.0-0034469402 10.1128/JVI.74.23.10930-10938.2000 (Pubitemid 32223957)
227. Verjans G. M. G. M., Remeijer L., Mooy C. M., Osterhaus A. D. M. E., Herpes simplex virus-specific T cells infiltrate the cornea of patients with herpetic stromal keratitis: no evidence for autoreactive T cells. Investigative Ophthalmology and Visual Science 2000 41 9 2607 2612 2-s2.0-0033861857 (Pubitemid 30624389)
228. + T cells in corneas of herpetic stromal keratitis patients. Journal of Infectious Diseases 1998 177 2 484 488 2-s2.0-0031908355 (Pubitemid 28063782)
229. Maertzdorf J., Osterhaus A. D. M. E., Verjans G. M. G. M., IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. Journal of Immunology 2002 169 10 5897 5903 2-s2.0-0037111404 (Pubitemid 35291695)
230. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J., Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. Journal of Clinical Investigation 1997 99 5 1092 1097 2-s2.0-0030948337 (Pubitemid 27123647)
231. Knaup B., Schünemann S., Wolff M. H., Subclinical reactivation of herpes simplex virus type 1 in the oral cavity. Oral Microbiology and Immunology 2000 15 5 281 283 2-s2.0-0033821822
232. Wald A., Zeh J., Selke S., Warren T., Ashley R., Corey L., Genital shedding of herpes simplex virus among men. Journal of Infectious Diseases 2002 186 supplement 1 S34 S39 2-s2.0-0037108420 10.1086/342969 (Pubitemid 35178847)
233. Leigh J. F., Acharya N., Cevallos V., Margolis T. P., Does asymptomatic shedding of herpes simplex virus on the ocular surface lead to false-positive diagnostic PCR results? British Journal of Ophthalmology 2008 92 3 435 436 2-s2.0-40549106469 10.1136/bjo.2007.122150 (Pubitemid 351363556)
234. Hobbs M. R., Jones B. B., Otterud B. E., Leppert M., Kriesel J. D., Identification of a herpes simplex labialis susceptibility region on human chromosome 21. Journal of Infectious Diseases 2008 197 3 340 346 2-s2.0-39349110213 10.1086/525540 (Pubitemid 351263414)
235. Stamm W. E., Handsfield H. H., Rompalo A. M., Ashley R. L., Roberts P. L., Corey L., The association between genital ulcer disease and acquisition of HIV infection in homosexual men. The Journal of the American Medical Association 1988 260 10 1429 1433 2-s2.0-0023675952
236. + T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. Journal of Virology 2006 80 11 5509 5515 2-s2.0-33646734890 10.1128/JVI.02659-05
237. Zhang X., Castelli F. A., Zhu X., Wu M., Maillère B., BenMohamed L., Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clinical and Vaccine Immunology 2008 15 9 1436 1449 2-s2.0-51649112932 10.1128/CVI.00123-08
238. Gierynska M., Kumaraguru U., Eo S. K., Lee S., Krieg A., Rouse B. T., Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. Journal of Virology 2002 76 13 6568 6576 2-s2.0-0036284414 10.1128/JVI.76.13.6568-6576.2002 (Pubitemid 34633522)
239. + cytotoxic T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America 1997 94 19 10289 10294 2-s2.0-0030961152 10.1073/pnas.94.19.10289 (Pubitemid 27407034)
240. Koelle D. M., Posavad C. M., Barnum G. R., Johnson M. L., Frank J. M., Corey L., Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. Journal of Clinical Investigation 1998 101 7 1500 1508 10.1172/JCI1758 (Pubitemid 28166848)
241. Toka F. N., Pack C. D., Rouse B. T., Molecular adjuvants for mucosal immunity. Immunological Reviews 2004 199 100 112 2-s2.0-2942573369 10.1111/j.0105-2896.2004.0147.x (Pubitemid 38736767)
242. Brandtzaeg P., Pabst R., Let's go mucosal: communication on slippery ground. Trends in Immunology 2004 25 11 570 577 2-s2.0-5644225732 10.1016/j.it.2004.09.005 (Pubitemid 39369732)
243. Bouvet J. P., Decroix N., Pamonsinlapatham P., Stimulation of local antibody production: parenteral or mucosal vaccination? Trends in Immunology 2002 23 4 209 213 2-s2.0-0036533644 10.1016/S1471-4906(02)02186-5 (Pubitemid 34260937)
244. + T cells in controlling HSV-1 latency ex vivo. Immunity 2005 23 5 515 525 2-s2.0-27744480039 10.1016/j.immuni.2005.09.017 (Pubitemid 41587891)
245. + T cell epitope-based vaccines against ocular herpes. Journal of Immunology 2010 184 5 2561 2571 2-s2.0-77951931542 10.4049/jimmunol.0902322
246. + T cells in trigeminal ganglia of latently infected mice. Journal of Virology 2009 83 5 2246 2254 2-s2.0-60049096721 10.1128/JVI.02234-08
247. Dasgupta G., Chentoufi A. A., Nesburn A. B., Wechsler S. L., BenMohamed L., New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Review of Vaccines 2009 8 8 1023 1035 2-s2.0-68049127746 10.1586/erv.09.60